Developing plasma DNA as a surrogate for tumor biopsy to identify tumor genetic alterations in patients with advanced breast cancer
Developing plasma DNA as a surrogate for tumor biopsy to identify tumor genetic alterations in patients with advanced breast cancer Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
NCT01836640
This study determined whether circulating tumor DNA in plasma is genetically reflective of the heterogeneity between primary and metastatic tumors within patients with advanced breast cancer.
Reference manuscript
Mary D Chamberlin, Jason D Wells, Kevin Shee, Jennifer R Bean, Jonathan D Marotti, Wendy A Wells, Heidi W Trask, Fred W Kolling, Ananta Bhatt, Peter A Kaufman, Gary N Schwartz, John M Gemery, Nancy J McNulty, Michael J Tsapakos, Richard J Barth, Bradley A Arrick, Jiang Gui, Todd W Miller.
Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19.